Supporting evidence

• LedgerMixed quarter based on: Limited earnings data — sync IR materials or configure FMP for consensus actuals.
• EventProvides capital for advancing HLP003, HLP004, and HLP005 programs, and for working capital and general corporate purposes.
• EventIndicates significant progress towards the critical Phase 3 readout in Q4 2026.

• EventProgresses the second pivotal trial for potential U.S. FDA New Drug Application in 2028.
• InitiativeOn track for next study design by the end of Q3 2026.
• InitiativeSuccessfully closed a $50 million underwritten offering.
• InitiativeAPPROACH study has surpassed 88% enrollment with top-line data expected in Q4 2026. EMBRACE study enrollment is ongoing.
• InitiativeTopline results announced, showing positive outcomes and durable effects.